All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The Lupus Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lupus Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lupus Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lupus Hub cannot guarantee the accuracy of translated content. The Lupus Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lupus Hub is an independent medical education platform, supported through a grant from AstraZeneca. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
What do HCPs need to know about LN and the prevention of progression to ESRD?
Featured
The Lupus Hub was pleased to speak to Murray Urowitz, University of Toronto, Toronto, CA. We asked, What do HCPs need to know about LN and the prevention of progression to end-stage renal disease (ESRD)?
What do HCPs need to know about LN and the prevention of progression to ESRD?
Urowitz begins by highlighting the incidence of ESRD in patients with lupus, with estimates ranging from 8% to 17% over 10 years. He then examines the factors associated with advancement to Grade 4 and 5 chronic kidney disease. He also presents data on the relationship between time to remission, number of flares in the first 5 years after initial remission, and the number of years a patient is on immunosuppressant therapy with the development of chronic kidney disease. Finally, he discusses how this data could inform lupus treatment and ultimately reduce the incidence of progression to ESRD.
More about...
Newsletter
Subscribe to get the best content related to lupus delivered to your inbox